Project Grant R01HL186178
Award Date 8/15/26
Completion Date 4/30/30
Dollars Obligated $514K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baton Rouge, LA 70803, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $842,500 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of cell-specific programmed death-ligand-1 (PD-L1) in cardiac pathophysiology following ischemic injury and in immune checkpoint inhibitor-mediated cardiotoxicity. The research examines how PD-L1 expression in fibroblasts and myeloid cells regulates repair and...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $737,455 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate provisional matrix-binding integrins as therapeutic targets in advanced atherosclerosis. The research examines how wound-associated extracellular matrix proteins promote atherogenic inflammation and plaque vulnerability, and tests whether combined deletion of α5 and αV integrins...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $732,705 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how cellular reductive state regulates inflammation resolution in atherosclerotic disease. The recipient will determine the influence of changing glutathione ratios (GSH:GSSG) on protein glutathionylation driving MERTK signaling in efferocytosis, the process by which...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $111,111 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms linking endoplasmic reticulum stress, lipid accumulation, and vascular inflammation in atherosclerosis. The research defines how the NCK1 adaptor protein integrates mechanical and metabolic stress to drive endothelial dysfunction. Aim 1 investigates how NCK1...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $737,242 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage one-carbon metabolism in atherosclerotic plaque stability. The recipient will conduct research examining serine hydroxymethyltransferase 2 (SHMT2)-dependent one-carbon metabolism in macrophages and its role in maintaining plaque stability and preventing atherosclerotic...
- The National Heart, Lung, and Blood Institute awarded The Washington University $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to conduct research into a multipotent fibroblast population and platelet-derived growth factor receptor beta–dependent immuno-fibrotic responses in heart failure. The research addresses cardiac fibrosis and left ventricular dysfunction in heart failure by investigating a novel population of stem cell antigen-1–expressing,...
- The National Heart, Lung, and Blood Institute awarded Florida State University $703,101 on July 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the role of structural elements in cardiac muscle contraction. The project addresses understudied functional regions of cardiac troponin C (CTNC), the calcium-binding subunit of the troponin complex that regulates calcium-dependent myofilament activation. The research targets cardiomyopathies arising from...
- The National Heart, Lung, and Blood Institute awarded the University of Arkansas $546,654 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for predicting and controlling cardiac fibrosis in heart failure patients with reduced ejection fraction. The project integrates systems mechanobiology modeling with experimental cell culture platforms and patient clinical data to identify cardiac fibroblast signaling feedback...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...